CSIMarket
 
The Cooper Companies Inc   (NASDAQ: COO)
 
Price: $67.5200 $-0.17 -0.251%
Day's High: $67.9000015258789 Week Perf: -3.17 %
Day's Low: $ 66.72 30 Day Perf: -11.53 %
Volume (M): 436,145 52 Wk High: $ 89.83
Volume (M$): $ 0 52 Wk Avg: $72.63
Open: $67.50 52 Wk Low: $58.89



 Market Capitalization (Millions $) 13,166
 Shares Outstanding (Millions) 195
 Employees 15,000
 Revenues (TTM) (Millions $) 4,230
 Net Income (TTM) (Millions $) 236
 Cash Flow (TTM) (Millions $) 23
 Capital Exp. (TTM) (Millions $) 384

Business Description


The Cooper Companies Inc. is a prominent American medical device company with a focus on ophthalmology and fertility. Established in 1958 by Martin Cooper, the company initially set out to produce contact lenses under the name eCooper Laboratories. Over the decades, it has grown substantially and now serves customers in more than 100 countries globally.

Business Segments

The Cooper Companies operates primarily through two segments:

1. CooperVision: This segment encompasses the companys vision care products. The CooperVision product line includes a variety of soft contact lenses, such as silicone hydrogel lenses, toric lenses for astigmatism, multifocal lenses for presbyopia, and lens care solutions. Key brands within this segment include Biofinity, Avaira, Proclear, and Clariti. The lenses are designed to address various eye conditions like myopia, hyperopia, and astigmatism.

2. CooperSurgical: This segment focuses on fertility and encompasses products and services aimed at assisting couples in becoming pregnant. CooperSurgical develops and markets medical devices and consumables for assisted reproductive technologies, such as in-vitro fertilization (IVF), positioning itself as a leader in this field with significant market presence in the United States, Europe, and Japan.

Strategic Growth and Acquisitions

The Cooper Companies has strategically expanded its product offerings and market reach through various acquisitions over the years. Notable acquisitions include:

- In 2014, the acquisition of Sauflon Pharmaceuticals, a British contact lens manufacturer, which bolstered CooperVisions presence in Europe.
- In 2017, the acquisition of the global women’s health business assets from Teva Pharmaceuticals, enhancing CooperSurgicals position in the women’s health market.

Customer Base and Operations

The company serves a diverse customer base, including eye care professionals, hospitals, clinics, and retail outlets. Additionally, it has developed an e-commerce platform that allows patients to purchase contact lenses directly from The Cooper Companies.

Corporate Structure and Workforce

Based in San Ramon, California, The Cooper Companies has a significant global presence with manufacturing and distribution facilities in the United States, Europe, and Asia. The company employs over 12,000 individuals worldwide, highlighting its expansive operations and commitment to innovation within the medical device sector.

Financial Performance

As of its most recent financial reports, The Cooper Companies has demonstrated strong growth, with reported revenues in the vicinity of $2.6 billion for the fiscal year 2020, reflecting its solid position in both the ophthalmic and fertility markets.

In summary, The Cooper Companies Inc. continues to evolve as a key player in the medical device industry, with a dual focus on enhancing eye care through innovative vision solutions and supporting fertility through advanced reproductive technologies.


   Company Address: 6101 Bollinger Canyon Road San Ramon 94583 CA
   Company Phone Number: 460-3600   Stock Exchange / Ticker: NASDAQ COO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BLCO        1.43% 
EYE   -0.47%    
MASI        0.01% 
MDT        1.1% 
WRBY   -1.36%    
WST   -0.99%    
• View Complete Report
   



Merger and Acquisition

CooperCompanies Acquires obp Surgical for $100 Million to Enhance Surgical Device Portfolio

Published Thu, Aug 1 2024 8:15 PM UTC

CooperCompanies Expands Surgical Portfolio with Acquisition of obp Surgical
On August 1, 2024, CooperCompanies (Nasdaq: COO), a leading player in the medical equipment and supplies sector, announced a strategic acquisition set to strengthen its CooperSurgical business unit. The company has acquired obp Surgical for approximately $100 million. This move comes as part of C...

Announcement

CooperCompanies Exceeds Market Expectations with Exceptional Second Quarter 2024 Result...

Published Thu, May 30 2024 8:15 PM UTC

CooperCompanies Announces Impressive Second Quarter 2024 Results, Solidifying its Position as a Global Leader in Medical DevicesSAN RAMON, Calif., May 30, 2024 - CooperCompanies (Nasdaq: COO), a prominent player in the medical device industry, has unveiled its financial results for the fiscal second quarter that concluded on April 30, 2024. The latest figures showcase the co...

Product Service News

CooperCompanies' 2023 ESG Report: Unleashing Change for a Healthier World and Sustainable Future

Published Thu, May 23 2024 8:15 PM UTC

CooperCompanies 2023 Environmental, Social, and Governance Report Highlights Efforts that Benefit People and the PlanetSAN RAMON, Calif., May 23, 2024 - CooperCompanies (Nasdaq: COO), a global leader in medical devices, today unveiled its highly anticipated 2023 Environmental, Social, and Governance (ESG) Report. This comprehensive report is a testament to the company s unwa...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 57.71
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.11
Price to Sales (Expected) -
Price to Book 1.6
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.08
Working Capital Ratio 1.37
Leverage Ratio (MRQ) 0.5
Total Debt to Equity 0.3
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.32

Per Share Current
Earnings (TTM) 1.17 $
Revenues (TTM) 21.69 $
Cash Flow (TTM) 0.12 $
Cash 0.71 $
Book Value 42.25 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 282,027
Net Income per Employee (TTM) 15,720
Receivable Turnover Ratio (TTM) 5.23
Inventory Turnover Ratio (TTM) 1.67
Asset Turnover Ratio (TTM) 0.34

Profitability Ratios Current
Gross Margin (MRQ) 68 %
Operating Margin (MRQ) -2.87 %
Net Margin (MRQ) -7.2 %
Net Cash Flow Margin (MRQ) 1.29 %
Effective Tax Rate (TTM) 42.84 %

Management Effectiveness Current
Return On Assets (TTM) 1.9 %
Return On Investment (TTM) 2.12 %
Return On Equity (TTM) 2.84 %
Dividend Yield -
Pay out Ratio (TTM) -



The Cooper Companies Inc's Segments
Coopervision Segment    66.9 % of total Revenue
Coopersurgical Segment    33.11 % of total Revenue
Toric and multifocal Coopervision Segment    33.74 % of total Revenue
Sphere other Coopervision Segment    33.16 % of total Revenue
Office and surgical Coopersurgical Segment    19.81 % of total Revenue
Fertility Coopersurgical Segment    13.3 % of total Revenue
CooperVision    66.9 % of total Revenue
CooperSurgical    33.11 % of total Revenue
United States    50.66 % of total Revenue
Europe    31.59 % of total Revenue
Rest of world    17.76 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.